161 related articles for article (PubMed ID: 24886765)
1. Novel or expanding current targets in fibrinolysis.
Wyseure T; Declerck PJ
Drug Discov Today; 2014 Sep; 19(9):1476-82. PubMed ID: 24886765
[TBL] [Abstract][Full Text] [Related]
2. A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects.
Zhou J; Kochan J; Yin O; Warren V; Zamora C; Atiee G; Pav J; Orihashi Y; Vashi V; Dishy V
J Thromb Haemost; 2017 May; 15(5):961-971. PubMed ID: 28211169
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the profibrinolytic properties of a bispecific antibody-based inhibitor against human and mouse thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1.
Wyseure T; Gils A; Declerck PJ
J Thromb Haemost; 2013 Nov; 11(11):2069-71. PubMed ID: 24034450
[No Abstract] [Full Text] [Related]
4. Antithrombotic properties of water-soluble carbon monoxide-releasing molecules.
Kramkowski K; Leszczynska A; Mogielnicki A; Chlopicki S; Fedorowicz A; Grochal E; Mann B; Brzoska T; Urano T; Motterlini R; Buczko W
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2149-57. PubMed ID: 22772756
[TBL] [Abstract][Full Text] [Related]
5. A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis.
Wang YX; da Cunha V; Vincelette J; Zhao L; Nagashima M; Kawai K; Yuan S; Emayan K; Islam I; Hosoya J; Sullivan ME; Dole WP; Morser J; Buckman BO; Vergona R
Thromb Haemost; 2007 Jan; 97(1):54-61. PubMed ID: 17200771
[TBL] [Abstract][Full Text] [Related]
6. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
7. [The fibrinolytic system and its activators].
Seifried E
Z Gesamte Inn Med; 1993; 48(6-7):272-82. PubMed ID: 8333223
[TBL] [Abstract][Full Text] [Related]
8. Serine-proteases as plasminogen activators in terms of fibrinolysis.
Flemmig M; Melzig MF
J Pharm Pharmacol; 2012 Aug; 64(8):1025-39. PubMed ID: 22775207
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacological potentials for activating the fibrinolytic system].
Markwardt F
Z Gesamte Inn Med; 1984 May; 39(10):209-13. PubMed ID: 6380126
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis.
Bunnage ME; Blagg J; Steele J; Owen DR; Allerton C; McElroy AB; Miller D; Ringer T; Butcher K; Beaumont K; Evans K; Gray AJ; Holland SJ; Feeder N; Moore RS; Brown DG
J Med Chem; 2007 Nov; 50(24):6095-103. PubMed ID: 17990866
[TBL] [Abstract][Full Text] [Related]
11. Is exogenous tissue plasminogen activator necessary for antithrombotic efficacy of an inhibitor of thrombin activatable fibrinolysis inhibitor (TAFI) in rats?
Bird E; Tamura J; Bostwick JS; Steinbacher TE; Stewart A; Liu Y; Baumann J; Feyen J; Tamasi J; Schumacher WA
Thromb Res; 2007; 120(4):549-58. PubMed ID: 17229457
[TBL] [Abstract][Full Text] [Related]
12. [Development of research into the physiology and pathophysiology of the fibrinolysis system].
Andreenko GV
Nauchnye Doki Vyss Shkoly Biol Nauki; 1985; (10):5-19. PubMed ID: 2933082
[TBL] [Abstract][Full Text] [Related]
13. Phosphinanes and Azaphosphinanes as Potent and Selective Inhibitors of Activated Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa).
Schaffner AP; Sansilvestri-Morel P; Despaux N; Ruano E; Persigand T; Rupin A; Mennecier P; Vallez MO; Raimbaud E; Desos P; Gloanec P
J Med Chem; 2021 Apr; 64(7):3897-3910. PubMed ID: 33764059
[TBL] [Abstract][Full Text] [Related]
14. Antithrombotic effects due to pharmacological modulation of thrombin-activatable fibrinolysis inhibitor in rats.
Soni H; Sharma A; Bhatt S; Jain MR; Patel PR
Pharmacology; 2008; 82(4):304-9. PubMed ID: 18936552
[TBL] [Abstract][Full Text] [Related]
15. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis.
van Veen SQ; Meijers JC; Levi M; van Gulik TM; Boermeester MA
Shock; 2007 May; 27(5):534-41. PubMed ID: 17438459
[TBL] [Abstract][Full Text] [Related]
16. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
17. Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation.
Colucci M; Semeraro N
Thromb Res; 2012 Mar; 129(3):314-9. PubMed ID: 22113149
[TBL] [Abstract][Full Text] [Related]
18. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
[TBL] [Abstract][Full Text] [Related]
19. Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction.
Wada T; Gando S; Mizugaki A; Yanagida Y; Jesmin S; Yokota H; Ieko M
Thromb Res; 2013 Jul; 132(1):e64-9. PubMed ID: 23726093
[TBL] [Abstract][Full Text] [Related]
20. A multiparameter test of clot formation and fibrinolysis for in-vitro drug screening.
Kostka B; Para J; Sikora J
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):611-8. PubMed ID: 17890947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
